{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:01:46Z","timestamp":1789758106074,"version":"4.0.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00404-8","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T20:55:08Z","timestamp":1763412908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["How should immune checkpoint inhibitor myocarditis be treated?"],"prefix":"10.1186","volume":"11","author":[{"given":"Sally","family":"Badaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Abbass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Tov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Bar-Sela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiel","family":"Bisharat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"4","key":"404_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The Blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364.","journal-title":"Nat Rev Cancer"},{"issue":"17","key":"404_CR2","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"33","author":"MA Postow","year":"2015","unstructured":"Postow MA, Callahan MK, Wolchok JD. Immune checkpoint Blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974\u201382.","journal-title":"J Clin Oncol"},{"issue":"12","key":"404_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and Meta-analysis. JAMA Oncol. 2018;4(12):1721\u20138.","journal-title":"JAMA Oncol"},{"issue":"16","key":"404_CR4","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"404_CR5","doi-asserted-by":"crossref","unstructured":"Jimenez-Alejandre R, Ruiz-Fernandez I, Martin P. Pathophysiology of immune checkpoint Inhibitor-Induced myocarditis. Cancers (Basel). 2022;14(18).","DOI":"10.3390\/cancers14184494"},{"key":"404_CR6","doi-asserted-by":"publisher","first-page":"1006860","DOI":"10.3389\/fimmu.2022.1006860","volume":"13","author":"M Liu","year":"2022","unstructured":"Liu M, Cheng X, Ni R, Zheng B, Huang S, Yang J. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis. Front Immunol. 2022;13:1006860.","journal-title":"Front Immunol"},{"issue":"12","key":"404_CR7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389.","journal-title":"Lancet Oncol"},{"issue":"1","key":"404_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jjcc.2022.07.009","volume":"81","author":"A Furukawa","year":"2023","unstructured":"Furukawa A, Tamura Y, Taniguchi H, Kawamura A, Nagase S, Hayashi A, et al. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. J Cardiol. 2023;81(1):63\u20137.","journal-title":"J Cardiol"},{"issue":"5","key":"404_CR9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaccao.2022.11.005","volume":"4","author":"J Moslehi","year":"2022","unstructured":"Moslehi J, Salem JE. Immune checkpoint inhibitor myocarditis treatment strategies and future directions. JACC CardioOncol. 2022;4(5):704\u20137.","journal-title":"JACC CardioOncol"},{"issue":"9","key":"404_CR10","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447\u201358.","journal-title":"Lancet Oncol"},{"issue":"41","key":"404_CR11","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"key":"404_CR12","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6).","DOI":"10.1136\/jitc-2021-002435"},{"issue":"3","key":"404_CR13","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","volume":"18","author":"JA Thompson","year":"2020","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN guidelines insights: management of Immunotherapy-Related Toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230\u201341.","journal-title":"J Natl Compr Canc Netw"},{"issue":"36","key":"404_CR14","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073\u2013126.","journal-title":"J Clin Oncol"},{"issue":"17","key":"404_CR15","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714\u201368.","journal-title":"J Clin Oncol"},{"issue":"10124","key":"404_CR16","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933.","journal-title":"Lancet"},{"issue":"21","key":"404_CR17","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical Features, Management, and outcomes of immune checkpoint Inhibitor-Related cardiotoxicity. Circulation. 2017;136(21):2085\u20137.","journal-title":"Circulation"},{"key":"404_CR18","doi-asserted-by":"crossref","unstructured":"Basso C, Myocarditis. N Engl J Med. 2022;387(16):1488\u2013500.","DOI":"10.1056\/NEJMra2114478"},{"key":"404_CR19","doi-asserted-by":"crossref","unstructured":"Murtagh G, deFilippi C, Zhao Q, Barac A. Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach. Front Cardiovasc Med. 2024;11:1350585.","DOI":"10.3389\/fcvm.2024.1350585"},{"issue":"6","key":"404_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","volume":"148","author":"LH Lehmann","year":"2023","unstructured":"Lehmann LH, Heckmann MB, Bailly G, Finke D, Procureur A, Power JR, et al. Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis. Circulation. 2023;148(6):473\u201386.","journal-title":"Circulation"},{"issue":"5","key":"404_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","volume":"4","author":"A Vasbinder","year":"2022","unstructured":"Vasbinder A, Chen Y, Procureur A, Gradone A, Azam TU, Perry D, et al. Biomarker Trends, Incidence, and outcomes of immune checkpoint Inhibitor-Induced myocarditis. JACC CardioOncol. 2022;4(5):689\u2013700.","journal-title":"JACC CardioOncol"},{"issue":"17","key":"404_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jacc.2011.08.026","volume":"58","author":"AS Jaffe","year":"2011","unstructured":"Jaffe AS, Vasile VC, Milone M, Saenger AK, Olson KN, Apple FS. Diseased skeletal muscle: a noncardiac source of increased Circulating concentrations of cardiac troponin T. J Am Coll Cardiol. 2011;58(17):1819\u201324.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"404_CR23","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.jacc.2018.01.070","volume":"71","author":"J Schmid","year":"2018","unstructured":"Schmid J, Liesinger L, Birner-Gruenberger R, Stojakovic T, Scharnagl H, Dieplinger B, et al. Elevated cardiac troponin T in patients with skeletal myopathies. J Am Coll Cardiol. 2018;71(14):1540\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"404_CR24","doi-asserted-by":"publisher","first-page":"100216","DOI":"10.1016\/j.esmoop.2021.100216","volume":"6","author":"D Delombaerde","year":"2021","unstructured":"Delombaerde D, Vervloet D, Franssen C, Croes L, Gremonprez F, Prenen H, et al. Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. ESMO Open. 2021;6(4):100216.","journal-title":"ESMO Open"},{"issue":"4","key":"404_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/CJI.0000000000000356","volume":"44","author":"E Ang","year":"2021","unstructured":"Ang E, Mweempwa A, Heron C, Ahn Y, Rivalland G, Ha LY, et al. Cardiac troponin I and T in checkpoint Inhibitor-associated myositis and myocarditis. J Immunother. 2021;44(4):162\u20133.","journal-title":"J Immunother"},{"issue":"5","key":"404_CR26","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jaccao.2024.07.001","volume":"6","author":"A Barac","year":"2024","unstructured":"Barac A, Wadlow RC, Deeken JF, deFilippi C. Cardiac troponin I and T in ICI myocarditis Screening, Diagnosis, and prognosis. JACC CardioOncol. 2024;6(5):804\u20137.","journal-title":"JACC CardioOncol"},{"key":"404_CR27","doi-asserted-by":"publisher","first-page":"1455347","DOI":"10.3389\/fimmu.2025.1455347","volume":"16","author":"X Man","year":"2025","unstructured":"Man X, Wang H, Chen C, Cong X, Sun L, Sun X, et al. Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review. Front Immunol. 2025;16:1455347.","journal-title":"Front Immunol"},{"issue":"2","key":"404_CR28","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological Characteristics, Diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"404_CR29","first-page":"13","volume":"7","author":"RS Zhang","year":"2021","unstructured":"Zhang RS, Padegimas A, Murphy KM, Evans PT, Peters CJ, Domenico CM, et al. Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with infliximab: a case series. Cardiooncology. 2021;7(1):13.","journal-title":"Cardiooncology"},{"key":"404_CR30","doi-asserted-by":"publisher","first-page":"1093383","DOI":"10.3389\/fcvm.2023.1093383","volume":"10","author":"J Xiao","year":"2023","unstructured":"Xiao J, Li X, Wang X, Guan Y, Liu H, Liang J, et al. Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience. Front Cardiovasc Med. 2023;10:1093383.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"404_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","volume":"5","author":"TG Norwood","year":"2017","unstructured":"Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, et al. Smoldering myocarditis following immune checkpoint Blockade. J Immunother Cancer. 2017;5(1):91.","journal-title":"J Immunother Cancer"},{"key":"404_CR32","doi-asserted-by":"publisher","first-page":"884776","DOI":"10.3389\/fphar.2022.884776","volume":"13","author":"Y Nakagomi","year":"2022","unstructured":"Nakagomi Y, Tajiri K, Shimada S, Li S, Inoue K, Murakata Y, et al. Immune checkpoint Inhibitor-Related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature. Front Pharmacol. 2022;13:884776.","journal-title":"Front Pharmacol"},{"issue":"15","key":"404_CR33","doi-asserted-by":"publisher","first-page":"e7460","DOI":"10.1002\/cam4.7460","volume":"13","author":"Y Gao","year":"2024","unstructured":"Gao Y, Zhang H, Qiu Y, Bian X, Wang X, Li Y. Early identification of severe immune checkpoint inhibitor associated myocarditis: from an electrocardiographic perspective. Cancer Med. 2024;13(15):e7460.","journal-title":"Cancer Med"},{"key":"404_CR34","doi-asserted-by":"publisher","first-page":"153779","DOI":"10.1016\/j.jelectrocard.2024.153779","volume":"86","author":"W Song","year":"2024","unstructured":"Song W, Chen Z, Zheng Y, Xu Y, Sun Y, Zhao Z, et al. Clinical and electrocardiographic characteristics of immune checkpoint inhibitor-related myocarditis. J Electrocardiol. 2024;86:153779.","journal-title":"J Electrocardiol"},{"key":"404_CR35","doi-asserted-by":"crossref","unstructured":"Zlotoff DA, Hassan MZO, Zafar A, Alvi RM, Awadalla M, Mahmood SS et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021;9(3).","DOI":"10.1136\/jitc-2020-002007"},{"issue":"1","key":"404_CR36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11886-025-02232-9","volume":"27","author":"AM Hachem","year":"2025","unstructured":"Hachem AM, Desai A, Beinart N, Ostos-Mendoza KC, Rodriguez ASL, de Leon Derby RD, et al. Updates in diagnosis and treatment of immune checkpoint inhibitor myocarditis. Curr Cardiol Rep. 2025;27(1):78.","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"404_CR37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","volume":"75","author":"M Awadalla","year":"2020","unstructured":"Awadalla M, Mahmood SS, Groarke JD, Hassan MZO, Nohria A, Rokicki A, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint Inhibitor-Related myocarditis. J Am Coll Cardiol. 2020;75(5):467\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"404_CR38","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al. Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint Inhibitor-Associated myocarditis. J Am Coll Cardiol. 2021;77(12):1503\u201316.","journal-title":"J Am Coll Cardiol"},{"key":"404_CR39","doi-asserted-by":"publisher","first-page":"110558","DOI":"10.1016\/j.ejrad.2022.110558","volume":"156","author":"SH Zhao","year":"2022","unstructured":"Zhao SH, Yun H, Chen CZ, Chen YY, Lin JY, Zeng MS, et al. Applying quantitative CMR parameters for detecting myocardial lesion in immune checkpoint inhibitors-associated myocarditis. Eur J Radiol. 2022;156:110558.","journal-title":"Eur J Radiol"},{"issue":"18","key":"404_CR40","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733\u201343.","journal-title":"Eur Heart J"},{"issue":"3","key":"404_CR41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1148\/radiol.211765","volume":"303","author":"F Cadour","year":"2022","unstructured":"Cadour F, Cautela J, Rapacchi S, Varoquaux A, Habert P, Arnaud F, et al. Cardiac MRI features and prognostic value in immune checkpoint Inhibitor-induced myocarditis. Radiology. 2022;303(3):512\u201321.","journal-title":"Radiology"},{"issue":"2","key":"404_CR42","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.acvd.2021.12.001","volume":"115","author":"S Ederhy","year":"2022","unstructured":"Ederhy S, Devos P, Pinna B, Funck-Brentano E, Abbar B, Fenioux C, et al. (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. Arch Cardiovasc Dis. 2022;115(2):114\u20136.","journal-title":"Arch Cardiovasc Dis"},{"key":"404_CR43","doi-asserted-by":"crossref","unstructured":"Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ et al. (68)Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis. J Immunother Cancer. 2021;9(10).","DOI":"10.1136\/jitc-2021-003594"},{"issue":"10","key":"404_CR44","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/ejhf.2265","volume":"23","author":"NL Palaskas","year":"2021","unstructured":"Palaskas NL, Segura A, Lelenwa L, Siddiqui BA, Subudhi SK, Lopez-Mattei J, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021;23(10):1725\u201335.","journal-title":"Eur J Heart Fail"},{"key":"404_CR45","doi-asserted-by":"publisher","first-page":"100006","DOI":"10.1016\/j.jhlto.2023.100006","volume":"2","author":"HA Ferreira Neves","year":"2023","unstructured":"Ferreira Neves HA, Yanaze Takamatsu G, Yuasa BS, Villatore VN, da Rocha GL, Lima Junior E. Right or left endomyocardial biopsy? A systematic review with meta-analysis about complications and safety. JHLT Open. 2023;2:100006.","journal-title":"JHLT Open"},{"issue":"2","key":"404_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem JE, Wiviott SD, Ederhy S, Cohen A, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in Cardio-Oncology. Circulation. 2019;140(2):80\u201391.","journal-title":"Circulation"},{"issue":"4","key":"404_CR47","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an international Cardio-Oncology society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u201399.","journal-title":"Eur Heart J"},{"issue":"10","key":"404_CR48","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333\u2013465.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"404_CR49","first-page":"30","volume":"11","author":"M Pereyra Pietri","year":"2025","unstructured":"Pereyra Pietri M, Farina JM, Scalia IG, Mahmoud AK, Roarke M, Wasef B, et al. Comparison of the diagnostic and prognostic value of criteria for immune checkpoint inhibitor related myocarditis. Cardiooncology. 2025;11(1):30.","journal-title":"Cardiooncology"},{"issue":"11","key":"404_CR50","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology study group of the heart failure association and the Cardio-Oncology Council of the European society of cardiology. Eur J Heart Fail. 2020;22(11):1966\u201383.","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"404_CR51","doi-asserted-by":"publisher","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","volume":"9","author":"J Alexandre","year":"2020","unstructured":"Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F, et al. Cardiovascular toxicity related to cancer treatment: A pragmatic approach to the American and European Cardio-Oncology guidelines. J Am Heart Assoc. 2020;9(18):e018403.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"404_CR52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jaccao.2020.12.001","volume":"3","author":"F Thuny","year":"2021","unstructured":"Thuny F, Alexandre J, Salem JE, Mirabel M, Dolladille C, Cohen-Solal A, et al. Management of immune checkpoint Inhibitor-Induced myocarditis: the French working group\u2019s plea for a pragmatic approach. JACC CardioOncol. 2021;3(1):157\u201361.","journal-title":"JACC CardioOncol"},{"key":"404_CR53","doi-asserted-by":"publisher","first-page":"1275254","DOI":"10.3389\/fimmu.2023.1275254","volume":"14","author":"C Wang","year":"2023","unstructured":"Wang C, Zhao G, Zhang Z, Yang L, Liu S, Li G, et al. Immune checkpoint inhibitor-associated myocarditis: a systematic analysis of case reports. Front Immunol. 2023;14:1275254.","journal-title":"Front Immunol"},{"issue":"24","key":"404_CR54","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint Inhibitor-Associated myocarditis. Circulation. 2020;141(24):2031\u20134.","journal-title":"Circulation"},{"issue":"5","key":"404_CR55","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaccao.2024.07.002","volume":"6","author":"NL Palaskas","year":"2024","unstructured":"Palaskas NL, Siddiqui BA, Deswal A. Steroids in immune checkpoint inhibitor myocarditis. JACC CardioOncol. 2024;6(5):800\u20133.","journal-title":"JACC CardioOncol"},{"issue":"4","key":"404_CR56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","volume":"20","author":"JA Thompson","year":"2022","unstructured":"Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, et al. Management of Immunotherapy-Related Toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(4):387\u2013405.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"404_CR57","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/FJC.0000000000001456","volume":"83","author":"JC Heemelaar","year":"2024","unstructured":"Heemelaar JC, Louisa M, Neilan TG. Treatment of immune checkpoint Inhibitor-associated myocarditis. J Cardiovasc Pharmacol. 2024;83(5):384\u201391.","journal-title":"J Cardiovasc Pharmacol"},{"key":"404_CR58","first-page":"101508","volume":"34","author":"T Yanase","year":"2021","unstructured":"Yanase T, Moritoki Y, Kondo H, Ueyama D, Akita H, Yasui T. Myocarditis and myasthenia Gravis by combined nivolumab and ipilimumab immunotherapy for renal cell carcinoma: A case report of successful management. Urol Case Rep. 2021;34:101508.","journal-title":"Urol Case Rep"},{"issue":"3","key":"404_CR59","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cjco.2020.11.004","volume":"3","author":"H Yogasundaram","year":"2021","unstructured":"Yogasundaram H, Alhumaid W, Chen JW, Church M, Alhulaimi N, Kimber S, et al. Plasma exchange for immune checkpoint Inhibitor-Induced myocarditis. CJC Open. 2021;3(3):379\u201382.","journal-title":"CJC Open"},{"issue":"7","key":"404_CR60","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/bjc.2017.253","volume":"117","author":"RY Tay","year":"2017","unstructured":"Tay RY, Blackley E, McLean C, Moore M, Bergin P, Gill S, et al. Successful use of equine anti-thymocyte Globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer. 2017;117(7):921\u20134.","journal-title":"Br J Cancer"},{"issue":"3","key":"404_CR61","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1056\/NEJMc1615251","volume":"376","author":"S Ederhy","year":"2017","unstructured":"Ederhy S, Voisin AL, Champiat S. Myocarditis with immune checkpoint Blockade. N Engl J Med. 2017;376(3):290\u20131.","journal-title":"N Engl J Med"},{"issue":"11","key":"404_CR62","doi-asserted-by":"publisher","first-page":"ytab342","DOI":"10.1093\/ehjcr\/ytab342","volume":"5","author":"MS Jespersen","year":"2021","unstructured":"Jespersen MS, Fano S, Stenor C, Moller AK. A case report of immune checkpoint inhibitor-related steroid-refractory myocarditis and myasthenia gravis-like myositis treated with abatacept and mycophenolate mofetil. Eur Heart J Case Rep. 2021;5(11):ytab342.","journal-title":"Eur Heart J Case Rep"},{"issue":"25","key":"404_CR63","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"ES Chung","year":"2003","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti TNFTACHFI. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107(25):3133\u201340.","journal-title":"Circulation"},{"key":"404_CR64","doi-asserted-by":"crossref","unstructured":"Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M et al. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-001887"},{"key":"404_CR65","doi-asserted-by":"crossref","unstructured":"Esfahani K, Buhlaiga N, Thebault P, Lapointe R, Johnson NA, Miller WH. Jr. Alemtuzumab for Immune-Related myocarditis due to PD-1 therapy. N Engl J Med. 2019;380(24):2375\u20136.","DOI":"10.1056\/NEJMc1903064"},{"issue":"4","key":"404_CR66","first-page":"397","volume":"50","author":"SJ Wu","year":"2022","unstructured":"Wu SJ, Liu XH, Wu W, Qian M, Li L, Zhang L, et al. [Tocilizumab therapy for immune checkpoint inhibitor associated myocarditis: a case report]. Zhonghua Xin Xue Guan Bing Za Zhi. 2022;50(4):397\u2013400.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"3","key":"404_CR67","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1016\/j.jtho.2019.09.080","volume":"15","author":"H Wang","year":"2020","unstructured":"Wang H, Tian R, Gao P, Wang Q, Zhang L. Tocilizumab for fulminant programmed death 1 Inhibitor-Associated myocarditis. J Thorac Oncol. 2020;15(3):e31\u20132.","journal-title":"J Thorac Oncol"},{"issue":"9","key":"404_CR68","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","volume":"31","author":"J Doms","year":"2020","unstructured":"Doms J, Prior JO, Peters S, Obeid M. Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol. 2020;31(9):1273\u20135.","journal-title":"Ann Oncol"},{"key":"404_CR69","doi-asserted-by":"crossref","unstructured":"Liu Y, Jiang L. Tofacitinib for treatment in immune-mediated myocarditis: the first reported cases. J Oncol Pharm Pract. 2020:1078155220947141.","DOI":"10.1177\/1078155220947141"},{"issue":"5","key":"404_CR70","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","volume":"13","author":"JE Salem","year":"2023","unstructured":"Salem JE, Bretagne M, Abbar B, Leonard-Louis S, Ederhy S, Redheuil A, et al. Abatacept\/Ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of Immune-Checkpoint inhibitor myocarditis. Cancer Discov. 2023;13(5):1100\u201315.","journal-title":"Cancer Discov"},{"key":"404_CR71","doi-asserted-by":"crossref","unstructured":"Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B et al. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J Immunother Cancer. 2022;10(4).","DOI":"10.1136\/jitc-2022-004699"},{"issue":"24","key":"404_CR72","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","volume":"380","author":"JE Salem","year":"2019","unstructured":"Salem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, et al. Abatacept for severe immune checkpoint Inhibitor-Associated myocarditis. N Engl J Med. 2019;380(24):2377\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"404_CR73","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.acvd.2024.12.005","volume":"118","author":"JE Salem","year":"2025","unstructured":"Salem JE, Ederhy S, Belin L, Zahr N, Tubach F, Procureur A, et al. Abatacept dose-finding phase II trial for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. Arch Cardiovasc Dis. 2025;118(2):106\u201315.","journal-title":"Arch Cardiovasc Dis"},{"key":"404_CR74","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Management of Immunotherapy Related Toxicities. Version 1.2025 \u2014 December 20, 2024. NCCN.org 2025 [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf"},{"issue":"12","key":"404_CR75","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(12):1217\u201338.","journal-title":"Ann Oncol"},{"issue":"6","key":"404_CR76","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1111\/1346-8138.17113","volume":"51","author":"R Toyoshima","year":"2024","unstructured":"Toyoshima R, Uehara J, Matsuzaki Y, Yoshimura A, Kitano S, Yoshino K. Troponin-guided utilization of Methylprednisolone pulse, intravenous immunoglobulin, and mycophenolate mofetil for successful control of immune checkpoint inhibitor-related myocarditis. J Dermatol. 2024;51(6):e207\u20138.","journal-title":"J Dermatol"},{"issue":"12","key":"404_CR77","doi-asserted-by":"publisher","first-page":"101375","DOI":"10.1016\/j.jacadv.2024.101375","volume":"3","author":"PF van den Berg","year":"2024","unstructured":"van den Berg PF, Bracun V, Noordman M, van der Meer P, Shi C, Oosting SF, et al. Elevations of cardiac troponin in patients receiving immune checkpoint inhibitors: data from a prospective study. JACC Adv. 2024;3(12):101375.","journal-title":"JACC Adv"},{"issue":"24","key":"404_CR78","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, et al. Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24):3158\u201376.","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00404-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00404-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00404-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T21:05:23Z","timestamp":1763413523000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00404-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["404"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00404-8","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"7 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from patients 1 and 2 and from the spouse of patient 3 who died during hospital stay.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}